Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Anand Devaraj et al.|The Lancet Respiratory Medicine|2020Cited by 558
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary FibrosisFernando J. Martínez, Timothy Albertson, Eric Yow et al.|JAMA|2021Cited by 78